1-9 of 9
Astrid McKeown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Vania Hungria, Marek Hus, Pawel Robak, Vera Zherebtsova, Ana Carolina de Almeida Ribas, Marcelo Pitombeira de Lacerda, Kihyun Kim, Sebastian Grosicki, Irwindeep Sandhu, Christopher Ward, Astrid McKeown, Hena Baig, Jie Ma, Benjamin Lariviere, Benga Kazeem, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Maria Victoria Mateos
Journal: Blood
Blood (2024) 144 (Supplement 1): 3359.
https://doi.org/10.1182/blood-2024-201543
Published: 2024
Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Phoebe Joy Ho, Roman Hajek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Maria Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Nick Pirooz, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Maria Victoria Mateos
Journal: Blood
Blood (2024) 144 (Supplement 1): 772.
https://doi.org/10.1182/blood-2024-200336
Published: 2024
Journal Articles

Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3

Geraldine Ferron-Brady, Adekemi Taylor, Josh Kaullen, Kishore Polireddy, Astrid McKeown, Neal Sule, Herbert Struemper
Journal: Blood
Blood (2023) 142 (Supplement 1): 6730.
https://doi.org/10.1182/blood-2023-178026
Published: 2023
Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Vania T.M Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Tamas Masszi, Jian Li, Marcelo Capra, Angelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Low, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalinska, Meletios Athanasios Dimopoulos
Journal: Blood
Blood (2023) 142 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2023-178009
Published: 2023
Journal Articles

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

Malin Hultcrantz, David Kleinman, Pavandeep Ghataorhe, Astrid McKeown, Wei He, Thomas Ling, Roxanne C Jewell, Joseph Brunner, Julie Byrne, Laurie Eliason, Emma Scott, Joanna Opalinska
Journal: Blood
Blood (2021) 138 (Supplement 1): 1645.
https://doi.org/10.1182/blood-2021-152224
Published: 2021
Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5288.
https://doi.org/10.1182/blood.V126.23.5288.5288
Published: 2015
Journal Articles

Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911)

Eugen Tausch, MD, Christina Galler, Richard Schlenk, MD, Peter Hillmen, MBChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Jiri Mayer, MD, Sebastian Grosicki, MD, Panagiotis Panagiotidis, Daniel Mertens, PhD, Astrid McKeown, PhD, Ira Gupta, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2014) 124 (21): 1992.
https://doi.org/10.1182/blood.V124.21.1992.1992
Published: 2014
Journal Articles

NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)

Eugen Tausch, MD, Philipp Beck, Richard F. Schlenk, MD, Sabrina Kless, Christina Galler, Peter Hillmen, MB ChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Susanne Danhauser-Riedl, MD, Astrid McKeown, PhD, Paul D P´B Winter, PhD, Ira V Gupta, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 527.
https://doi.org/10.1182/blood.V122.21.527.527
Published: 2013
Journal Articles

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Peter Hillmen, MB ChB, PhD, Tadeusz Robak, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Eva Kimby, MD, Anna Schuh, MD, Thomas Boyd, MD, Marco Montillo, MD, Astrid McKeown, PhD, Jodi L Carey, RN, BSN, Ira V Gupta, MD, Chai-Ni Chang, MS, Steen Lisby, MD, DMSc, Fritz Offner, MD
Journal: Blood
Blood (2013) 122 (21): 528.
https://doi.org/10.1182/blood.V122.21.528.528
Published: 2013